189 related articles for article (PubMed ID: 24201220)
1. Decreased expression of 14-3-3σ is predictive of poor prognosis for patients with human uterine papillary serous carcinoma.
Suzuki F; Nagase S; Suzuki K; Oba E; Hiroki E; Matsuda Y; Akahira J; Nishigori H; Sugiyama T; Otsuki T; Yoshinaga K; Takano T; Niikura H; Ito K; Sasano H; Yaegashi N
Tohoku J Exp Med; 2013 Nov; 231(3):193-9. PubMed ID: 24201220
[TBL] [Abstract][Full Text] [Related]
2. Loss of p53 function in uterine papillary serous carcinoma.
Kovalev S; Marchenko ND; Gugliotta BG; Chalas E; Chumas J; Moll UM
Hum Pathol; 1998 Jun; 29(6):613-9. PubMed ID: 9635683
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].
Ren YL; Wang HY; Zhou XY; Shan BE; Yang WT; Shen L; Shi DR
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):367-71. PubMed ID: 20646447
[TBL] [Abstract][Full Text] [Related]
4. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
Zheng W; Liang SX; Yu H; Rutherford T; Chambers SK; Schwartz PE
Int J Surg Pathol; 2004 Jul; 12(3):207-23. PubMed ID: 15306933
[TBL] [Abstract][Full Text] [Related]
5. p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium.
Busmanis I; Ho TH; Tan SB; Khoo KS
Ann Acad Med Singap; 2005 Aug; 34(7):421-5. PubMed ID: 16123814
[TBL] [Abstract][Full Text] [Related]
6. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
[TBL] [Abstract][Full Text] [Related]
7. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Positive Pelvic Washings in Uterine Papillary Serous Carcinoma Confined to an Endometrial Polyp.
Hanley KZ; Fadare O; Fisher KE; Atkins KA; Mosunjac MB
Int J Gynecol Pathol; 2016 May; 35(3):249-55. PubMed ID: 26535985
[TBL] [Abstract][Full Text] [Related]
9. p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.
Bancher-Todesca D; Gitsch G; Williams KE; Kohlberger P; Neunteufel W; Obermair A; Heinze G; Breitenecker G; Hacker NF
Gynecol Oncol; 1998 Oct; 71(1):59-63. PubMed ID: 9784320
[TBL] [Abstract][Full Text] [Related]
10. Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma.
Schmidt M; Segev Y; Sadeh R; Suzan E; Feferkorn I; Kaldawy A; Kligun G; Lavie O
Int J Gynecol Cancer; 2018 Sep; 28(7):1311-1317. PubMed ID: 29958235
[TBL] [Abstract][Full Text] [Related]
11. Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary?
Peled Y; Aviram A; Krissi H; Gershoni A; Sabah G; Levavi H; Eitan R
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):498-502. PubMed ID: 26235227
[TBL] [Abstract][Full Text] [Related]
12. Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma.
Morgan J; Hoekstra AV; Chapman-Davis E; Hardt JL; Kim JJ; Buttin BM
Gynecol Oncol; 2009 Aug; 114(2):293-8. PubMed ID: 19476987
[TBL] [Abstract][Full Text] [Related]
13. A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).
Chen L; Liu X; Li M; Wang S; Zhou H; Liu L; Cheng X
Cancer Med; 2020 Feb; 9(3):988-998. PubMed ID: 31846222
[TBL] [Abstract][Full Text] [Related]
14. Methylation profiles of endometrioid and serous endometrial cancers.
Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783
[TBL] [Abstract][Full Text] [Related]
15. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
[TBL] [Abstract][Full Text] [Related]
17. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
[TBL] [Abstract][Full Text] [Related]
18. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma.
Togami S; Sasajima Y; Oi T; Ishikawa M; Onda T; Ikeda S; Kato T; Tsuda H; Kasamatsu T
Cancer Sci; 2012 May; 103(5):926-32. PubMed ID: 22329832
[TBL] [Abstract][Full Text] [Related]
20. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features.
Liang SX; Chambers SK; Cheng L; Zhang S; Zhou Y; Zheng W
Int J Surg Pathol; 2004 Oct; 12(4):319-31. PubMed ID: 15494858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
